Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CTSV | O60911 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
| ▸ | CTSF | Q9UBX1 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.39 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.39 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.39 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.39 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.39 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964263 | 0.88 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL9721933 | 0.86 | TSHR (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19KMT2A | |
| SCHEMBL15719169 | 0.86 | CTSL (0.43) | SMN1; SMN2NPC1RAB9ACTSLCTSB | |
| SCHEMBL2707159 | 0.84 | DDB1 (0.49) | SMN1; SMN2PKM | |
| SCHEMBL9721728 | 0.79 | TACR1 (0.57) | NPC1RAB9ACYP2C19KMT2AMEN1 | |
| SCHEMBL2824395 | 0.78 | NPC1 (0.30) | NPC1 | |
| Hydrochloric Acid SCHEMBL9721535 | 0.78 | TACR1 (0.58) | CYP2C19ALDH1A1TACR1GRIN1GRIN2B | |
| SCHEMBL28164934 | 0.77 | TACR1 (0.40) | CTSLCTSBCTSKCTSVCTSS | |
| SCHEMBL2707122 | 0.77 | PSEN1 (0.41) | CTSLCTSBCTSKCTSVCTSS | |
| SCHEMBL2145928 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2NPC1RAB9ACTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NUEVOLUTION A/S (DK) | 2023-08-31 | — | — | US | disclosed |
| EP-3233827-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | Aziende Chimiche Riunite Angelini Francesco A.C.R. (IT) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016096686-A1 | ANTIBACTERIAL COMPOUNDS HAVING BROAD SPECTRUM OF ACTIVITY | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 2016-06-23 | — | — | WO | disclosed |
| EP-2226322-B1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO CO LTD (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-8927588-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-13 | — | — | US | disclosed |
| US-8536197-B2 | Imidazole carbonyl compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-09-17 | — | — | US | disclosed |
| WO-2012025811-A1 | INDOLYLPYRIMIDINES AS MODULATORS OF GPR119 | LUPIN LIMITED (IN) | 2012-03-01 | — | — | WO | disclosed |
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-12-09 | — | — | US | disclosed |
| EP-2226322-A1 | IMIDAZOLE CARBONYL COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2010-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271937-A1 | COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS | NCOA1, NR1H2, NCOA3 | SMN1; SMN2 4320/4885NPC1 155/4885RAB9A 3896/4885 |
| US-20100311966-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | SMN1; SMN2 4001/4885NPC1 1573/4885RAB9A 2042/4885 |
| US-20140073622-A1 | IMIDAZOLE CARBONYL COMPOUND | TOP1, TOP2B, TOP2A | SMN1; SMN2 3604/4885NPC1 630/4885RAB9A 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.